Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
Leerink Partners

Leerink Partners Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Leerink Partners. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leerink Partners' equity research team. MarketBeat is not affiliated with or endorsed by Leerink Partners.

Average Return
00.00% 12-Month ROI
Total Ratings
422 Last 12 Months
Buy Ratings
287 Last 12 Months
Sell Ratings
2 Last 12 Months
Companies Covered
241 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
0 Results
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$452.29
+1.9%
10/21/2026Set Price Target$473.00 ➝ $503.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,275.50
-2.4%
10/21/2026Boost Price Target$1,309.00 ➝ $1,316.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 10/21/2026
Novogen Limited stock logo
KZIA
Novogen
$7.81
-3.2%
10/20/2026Initiated Coverage$30.00OutperformView details for Leerink Partners rating of Novogen (NASDAQ:KZIA) on 10/20/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$587.50
+0.5%
10/19/2026Boost Price Target$685.00 ➝ $725.00OutperformView details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 10/19/2026
TRAX
First Tracks Biotherapeutics
$44.05
+2.1%
10/16/2026Boost Price Target$70.00 ➝ $90.00OutperformView details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 10/16/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$264.13
-1.3%
10/14/2026Lower Price Target$276.00 ➝ $272.00OutperformView details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 10/14/2026
DENTSPLY SIRONA Inc. stock logo
XRAY
DENTSPLY SIRONA
$9.43
-0.7%
10/14/2026Lower Price Target$14.00 ➝ $10.00Market PerformView details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 10/14/2026
Envista Holdings Corporation stock logo
NVST
Envista
$23.62
-1.5%
10/14/2026Lower Price Target$35.00 ➝ $32.00OutperformView details for Leerink Partners rating of Envista (NYSE:NVST) on 10/14/2026
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$84.96
-1.2%
10/14/2026Set Price Target$96.00 ➝ $92.00Market PerformView details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 10/14/2026
Align Technology, Inc. stock logo
ALGN
Align Technology
$154.51
-0.6%
10/14/2026Lower Price Target$235.00 ➝ $215.00OutperformView details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 10/14/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$0.77
+0.6%
10/12/2026Initiated Coverage$4.00OutperformView details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 10/12/2026
CVS Health Corporation stock logo
CVS
CVS Health
$93.55
-1.0%
10/12/2026Lower Price Target$119.00 ➝ $112.00OutperformView details for Leerink Partners rating of CVS Health (NYSE:CVS) on 10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
$1.23
-3.1%
10/12/2026Initiated Coverage$6.00OutperformView details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 10/12/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$37.22
-3.7%
10/12/2026Initiated Coverage$130.00OutperformView details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 10/12/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$138.43
-0.8%
10/12/2026Reiterated Rating$150.00 ➝ $190.00OutperformView details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 10/12/2026
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$8.65
-1.7%
10/12/2026Initiated Coverage$40.00OutperformView details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 10/12/2026
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$27.99
-3.6%
10/12/2026Initiated Coverage$34.00Market PerformView details for Leerink Partners rating of Vera Therapeutics (NASDAQ:VERA) on 10/12/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$9.84
-8.3%
10/9/2026Boost Price Target$13.00 ➝ $19.00OutperformView details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$45.67
-0.7%
10/9/2026Lower Price Target$60.00 ➝ $55.00View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/9/2026
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$279.47
+0.4%
10/8/2026 Boost Price Target$280.00 ➝ $310.00OutperformView details for Leerink Partners rating of IQVIA (NYSE:IQV) on 10/8/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.53
-4.9%
10/7/2026Reiterated Rating$4.00 ➝ $1.00Outperform ➝ Market PerformView details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026
Cencora, Inc. stock logo
COR
Cencora
$330.77
-2.3%
10/7/2026Boost Price Target$380.00 ➝ $388.00OutperformView details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2026
Caribou Biosciences, Inc. stock logo
CRBU
Caribou Biosciences
$0.53
-4.9%
10/7/2026Downgrade$1.00Outperform ➝ Market PerformView details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026
McKesson Corporation stock logo
MCK
McKesson
$1,000.53
-1.2%
10/7/2026Boost Price Target$1,030.00 ➝ $1,070.00OutperformView details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2026
OmniAb, Inc. stock logo
OABI
OmniAb
$4.66
-2.5%
10/7/2026Boost Price Target$10.00 ➝ $12.00OutperformView details for Leerink Partners rating of OmniAb (NASDAQ:OABI) on 10/7/2026
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.29
-0.9%
10/7/2026Lower Price Target$7.00 ➝ $4.00Market PerformView details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/7/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$61.58
-2.3%
10/5/2026Downgrade$73.00 ➝ $59.00Outperform ➝ Market PerformView details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 10/5/2026
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
$13.17
-3.4%
10/5/2026Initiated Coverage$26.00OutperformView details for Leerink Partners rating of Oric Pharmaceuticals (NASDAQ:ORIC) on 10/5/2026
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
$2.21
-8.3%
10/5/2026Initiated Coverage$4.00 ➝ $8.00Market Perform ➝ OutperformView details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 10/5/2026
10x Genomics stock logo
TXG
10x Genomics
$71.55
+2.6%
9/29/2026Boost Price Target$40.00 ➝ $90.00Market PerformView details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$139.92
+3.3%
9/29/2026Boost Price Target$160.00 ➝ $190.00OutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/29/2026
Illumina, Inc. stock logo
ILMN
Illumina
$269.42
+0.0%
9/29/2026Boost Price Target$220.00 ➝ $300.00OutperformView details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 9/29/2026
Bruker Corporation stock logo
BRKR
Bruker
$57.59
+0.5%
9/29/2026Boost Price Target$60.00 ➝ $80.00OutperformView details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 9/29/2026
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$31.51
-1.2%
9/23/2026Boost Price Target$30.00 ➝ $33.00Market PerformView details for Leerink Partners rating of Acadia Healthcare (NASDAQ:ACHC) on 9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$48.73
+1.3%
9/23/2026Lower Price Target$90.00 ➝ $81.00OutperformView details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 9/23/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$29.25
+1.0%
9/23/2026Boost Price Target$70.00 ➝ $88.00OutperformView details for Leerink Partners rating of Celldex Therapeutics (NASDAQ:CLDX) on 9/23/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$2.80
-3.1%
9/23/2026Reiterated Rating$15.00OutperformView details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 9/23/2026
OBX
Obsidian Therapeutics
$13.98
+0.3%
9/22/2026 Initiated Coverage$32.00OutperformView details for Leerink Partners rating of Obsidian Therapeutics (NASDAQ:OBX) on 9/22/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.63
-7.5%
9/21/2026 Boost Price Target$36.00 ➝ $40.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/21/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$523.93
-2.1%
9/21/2026 Initiated Coverage$594.00OutperformView details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/21/2026
$29.97 or $0 today (Ad)

The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.tc pixel

Click here to claim your free copy before the price changes
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$12.80
-2.4%
9/18/2026Set Price Target$32.00OutperformView details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026
Ardent Health, Inc. stock logo
ARDT
Ardent Health
$12.28
-0.7%
9/18/2026Reiterated Rating$14.00OutperformView details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 9/18/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$12.80
-2.4%
9/18/2026Upgrade$32.00Strong-BuyView details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$2.92
-3.3%
9/18/2026Initiated Coverage$9.00OutperformView details for Leerink Partners rating of Entera Bio (NASDAQ:ENTX) on 9/18/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$469.45
+0.5%
9/18/2026Reiterated Rating$492.00OutperformView details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 9/18/2026
Tenet Healthcare Corporation stock logo
THC
Tenet Healthcare
$268.13
-0.9%
9/18/2026Reiterated Rating$309.00OutperformView details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 9/18/2026
Universal Health Services, Inc. stock logo
UHS
Universal Health Services
$186.88
-0.7%
9/18/2026Boost Price Target$198.00 ➝ $205.00OutperformView details for Leerink Partners rating of Universal Health Services (NYSE:UHS) on 9/18/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$139.92
+3.3%
9/17/2026Boost Price Target$120.00 ➝ $160.00OutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/17/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$19.16
-0.9%
9/14/2026Boost Price Target$24.00 ➝ $27.00OutperformView details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 9/14/2026
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$2.35
+3.5%
9/14/2026Initiated Coverage$13.00OutperformView details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 9/14/2026
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$60.59
-3.9%
9/14/2026 Initiated Coverage$98.00Hold ➝ OutperformView details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/14/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$89.27
-1.8%
9/14/2026 Initiated Coverage$133.00OutperformView details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 9/14/2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$10.20
-6.1%
9/10/2026Boost Price Target$12.00 ➝ $16.00OutperformView details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 9/10/2026
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
$2.66
-6.7%
9/10/2026Lower Price Target$27.00OutperformView details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.41
+2.4%
9/9/2026Boost Price Target$50.00 ➝ $65.00OutperformView details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026
Evommune, Inc. stock logo
EVMN
Evommune
$5.09
-2.4%
9/9/2026Lower Price Target$28.00 ➝ $22.00OutperformView details for Leerink Partners rating of Evommune (NYSE:EVMN) on 9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.44
+0.1%
9/9/2026Initiated Coverage$24.00OutperformView details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.96
-2.3%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.38
-0.5%
9/9/2026Initiated Coverage$23.00OutperformView details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$5.74
-18.1%
9/9/2026Initiated Coverage$10.00Market PerformView details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
$28.44
+1.0%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026
Viatris Inc. stock logo
VTRS
Viatris
$18.00
-2.6%
9/9/2026Initiated Coverage$20.00OutperformView details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.38
-0.5%
9/9/2026Initiated Coverage$23.00OutperformView details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$72.61
-1.5%
9/9/2026 Initiated Coverage$104.00OutperformView details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 9/9/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$17.44
+0.1%
9/9/2026Initiated Coverage$24.00OutperformView details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$22.96
-2.3%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026
Harrow, Inc. stock logo
HROW
Harrow
$28.44
+1.0%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$145.25
-1.4%
9/9/2026Boost Price Target$127.00 ➝ $161.00OutperformView details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 9/9/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$3.24
+24.6%
9/9/2026Initiated Coverage$4.00OutperformView details for Leerink Partners rating of Nautilus Biotechnology (NASDAQ:NAUT) on 9/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.42
+0.2%
9/9/2026Initiated Coverage$28.00Market PerformView details for Leerink Partners rating of Pacira BioSciences (NASDAQ:PCRX) on 9/9/2026
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$5.74
-18.1%
9/9/2026Initiated Coverage$10.00HoldView details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$39.39
-2.0%
9/9/2026Initiated Coverage$45.00OutperformView details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 9/9/2026
Viatris Inc. stock logo
VTRS
Viatris
$18.00
-2.6%
9/9/2026Initiated Coverage$20.00OutperformView details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$4.03
-6.7%
9/8/2026Set Price Target$15.00View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/8/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.63
-7.5%
9/1/2026 Initiated Coverage$36.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
$15.02
-9.4%
9/1/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.63
-7.5%
9/1/2026 Initiated Coverage$36.00OutperformView details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026
Latigo Biotherapeutics, Inc. stock logo
LTGO
Latigo Biotherapeutics
$15.02
-9.4%
9/1/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026
ATTO
Attovia Therapeutics
$13.83
-4.6%
8/31/2026Initiated Coverage$52.00OutperformView details for Leerink Partners rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026
Scribe Therapeutics Inc. stock logo
SCTX
Scribe Therapeutics
$15.40
-14.3%
8/18/2026Initiated Coverage$37.00OutperformView details for Leerink Partners rating of Scribe Therapeutics (NASDAQ:SCTX) on 8/18/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$805.02
-1.7%
8/17/2026Boost Price Target$641.00 ➝ $824.00Market PerformView details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026
Freenome stock logo
FRNM
Freenome
$12.77
-2.5%
8/14/2026Initiated Coverage$18.00OutperformView details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$303.53
-1.4%
8/14/2026Initiated Coverage$330.00OutperformView details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$15.47
-0.5%
8/12/2026Upgrade$12.00 ➝ $13.00Underperform ➝ Market PerformView details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026
Cardinal Health, Inc. stock logo
CAH
Cardinal Health
$249.47
-2.4%
8/11/2026Set Price Target$292.00View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026
Tenax Therapeutics, Inc. stock logo
TENX
Tenax Therapeutics
$1.72
-2.3%
8/11/2026 Set Price Target$4.00View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.50
8/11/2026 Upgrade$4.00Market Perform ➝ OutperformView details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026
Natera, Inc. stock logo
NTRA
Natera
$403.95
+0.6%
8/7/2026 Set Price Target$330.00View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.57
+0.8%
8/7/2026Downgrade$1.00Outperform ➝ Market PerformView details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$125.63
+0.9%
8/7/2026Upgrade$83.00 ➝ $110.00Market Perform ➝ OutperformView details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026
This free guide explains options the way they should be taught (Ad)

Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.tc pixel

Claim your free options guide and start building real trading knowledge
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.54
-2.2%
8/6/2026 Set Price Target$5.00View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$64.53
-1.2%
8/6/2026 Downgrade$52.00Outperform ➝ Market PerformView details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026
Insulet Corporation stock logo
PODD
Insulet
$149.01
+0.6%
8/6/2026Downgrade$247.00 ➝ $145.00Outperform ➝ Market PerformView details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026
AbbVie Inc. stock logo
ABBV
AbbVie
$285.66
+0.2%
8/5/2026 Boost Price Target$245.00 ➝ $279.00OutperformView details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 8/5/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
$11.46
-4.4%
8/4/2026Upgrade$11.00 ➝ $17.00Market Perform ➝ OutperformView details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.28
-0.6%
8/4/2026 Lower Price Target$30.00 ➝ $23.00OutperformView details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$99.80
-0.3%
8/3/2026 Set Price Target$102.50View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026
Incyte Corporation stock logo
INCY
Incyte
$115.71
-1.0%
8/3/2026Boost Price Target$131.00 ➝ $155.00OutperformView details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$99.80
-0.3%
8/3/2026 DowngradeStrong-Buy ➝ HoldView details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$61.58
-2.3%
7/31/2026Boost Price Target$67.00 ➝ $73.00OutperformView details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 7/31/2026

MarketBeat's community ratings are surveys of what our community members think about Leerink Partners and other research firms in the last 90 days. Vote "Outperform" if you believe Leerink Partners's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Leerink Partners's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
0.0out of 5 (last 90 days)
0 of 5 stars
OUTPERFORM VOTES
0 Believe will outperform the market
UNDERPERFORM VOTES
0 Believe will underperform the market

Leerink Partners' equity research team has issued ratings on 234 companies across 4 sectors over the past 12 months, covered by 20 analysts. The Leerink Partners analysts below are listed by number of ratings issued in the last year.

Leerink Partners Stock Coverage by Sector

Leerink Partners concentrates its research most heavily in Healthcare (95.9%), Industrials (0.4%) and Consumer Discretionary (0.4%). The chart below shows how Leerink Partners' 241 rated companies are distributed across all 4 sectors it covers.

Leerink Partners - Frequently Asked Questions

Leerink Partners' analysts currently have buy-equivalent ratings on 189 companies. Recent upgrades to buy include Eloxx Pharmaceuticals, Innate Pharma, Halozyme Therapeutics, Replimune Group and Humana.

Leerink Partners' highest-rated analysts by MarketBeat's accuracy score include Andrew Berens, Puneet Souda and Faisal Khurshid. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 21 analysts at Leerink Partners.

Leerink Partners has the deepest coverage in Healthcare (95.9% of rated companies), Industrials (0.4% of rated companies), Finance (0.4% of rated companies) and Consumer Discretionary (0.4% of rated companies).

Leerink Partners issued 422 ratings over the last 12 months across 241 companies — an average of roughly 35 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Leerink Partners analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Leerink Partners uses Outperform, Market Perform, and Underperform as their equivalents.